

11 September 2025

ASX Announcement

## Passing of Director - Phyllis Gardner

---

**Firebrick Pharma Limited** (ASX:FRE) (**Firebrick, Company**) advises with great sadness the passing of Dr Phyllis Gardner, Non-Executive Director of Firebrick. Phyllis has been a very valuable Board member over the last several years. Her experience, insights and unflinching support will be greatly missed by all of us at Firebrick.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

### About Firebrick (ASX:FRE)

Firebrick Pharma is a pharmaceutical innovator developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). The Company has developed and is now commercialising Nasodine® Nasal Spray (0.5% PVP-I) and has several other products in development. Firebrick has already introduced Nasodine Nasal Spray into the United States, Singapore and Fiji & South Pacific, with a launch in the Philippines expected in 2026.

**Media enquiries:**

Heidi Cuthbert  
+61 411 272 366  
[heidi.cuthbert@multiplier.com.au](mailto:heidi.cuthbert@multiplier.com.au)

**Investor enquiries:**

[Investors@firebrickpharma.com](mailto:Investors@firebrickpharma.com)